Open $48.33
Day Range 47.15 - 48.38
52 Week Range 33.36 - 51.86
Market Cap $270.97B
Shares Outstanding N/A
Public Float 5.6B
Beta 0.67
Rev. per Employee $533.86K
P/E Ratio 14.05
EPS $3.37
Yield 3.30%
Dividend $0.39
Ex-Dividend Date Nov 4, 2021
Short Interest 58.88M 10/29/21
% of Float Shorted 1.05%
Average Volume 34.35M

5 Day	4.07%
1 Month	13.02%
3 Month	-1.85%
YTD	28.50%
1 Year	29.09%

Sell
Under
Hold
Over
Buy

Number of Ratings 21 Full Ratings

Pfizer and BioNTech seek backing of COVID-19 booster for those 18 and over, as U.S. deaths continue to average 1,200 a day

Nov. 9, 2021 at 10:56 a.m. ET by Ciara Linnane

Pfizer asks FDA to authorize COVID-19 booster shot for all adults

Nov. 9, 2021 at 3:17 p.m. ET by Jaimy Lee

Pfizer and BioNTech ask FDA for emergency use authorization for COVID booster for adults aged 18 and older

Nov. 9, 2021 at 2:59 p.m. ET by Ciara Linnane

Terry Bradshaw blasts Aaron Rodgers over vaccine status: ‘You lied to everyone’

Nov. 8, 2021 at 1:03 p.m. ET by Weston Blasi

Health Canada Approves Pfizer Booster Dose

Nov. 9, 2021 at 11:46 a.m. ET

BioNTech stock reverses lower after earnings report, in which profit and revenue beat expectations

Nov. 9, 2021 at 11:12 a.m. ET by Tomi Kilgore

Pfizer to seek authorization of COVID-19 pill ‘as soon as possible’

Nov. 5, 2021 at 12:08 p.m. ET by Jaimy Lee

Barron's

BioNTech Stock Is Getting a Lift. Earnings Were Strong.

Nov. 9, 2021 at 8:44 a.m. ET by Barron's

Biohaven, Pfizer in Collaboration to Commercialize Rimegepant

Nov. 9, 2021 at 8:17 a.m. ET

Biohaven's stock slides 15% on deal with Pfizer for its migraine drug

Nov. 9, 2021 at 8:07 a.m. ET by Jaimy Lee

BioNTech Lifts 2021 Covid-19 Vaccine Revenue Outlook to Up to Almost $20 Billion

Nov. 9, 2021 at 7:43 a.m. ET

Merck stock rallies after U.S. plans to buy 1.4 million more COVID-19 pill courses for $1 billion if authorized

Nov. 9, 2021 at 6:14 a.m. ET by Tomi Kilgore

Pfizer Inc. stock falls Monday, underperforms market

Nov. 8, 2021 at 5:15 p.m. ET by MarketWatch Automation

S&P 500 ends at record for 8th day in a row, the longest streak of records since 1997, on renewed optimism

Nov. 8, 2021 at 5:15 a.m. ET by Mark DeCambre

Benchmark 10-year Treasury rate logs largest rise in 3 weeks but holds around 1.50%

Nov. 8, 2021 at 7:43 a.m. ET by Mark DeCambre

Barron's

Regeneron’s Covid Drug Could Be an Alternative to Vaccines

Nov. 8, 2021 at 8:37 a.m. ET by Barron's

Infrastructure, Jobs & Covid Relief

Nov. 8, 2021 at 8:00 a.m. ET

Barron's

Good Jobs Report Points to Continued Good Times for Stocks

Nov. 5, 2021 at 8:32 p.m. ET by Barron's

Moderna cites supply-chain ‘complexity’ as COVID-19 vaccine sales come in $1 billion short

Nov. 4, 2021 at 4:32 p.m. ET by Jaimy Lee

Barron's

How Long Will the Stock Market Rally? At Least Until New Year’s.

Nov. 5, 2021 at 9:01 p.m. ET by Barron's

No Headlines Available

Why BioNTech Is Tumbling Today

Nov. 9, 2021 at 4:19 p.m. ET on Motley Fool

OCGN Stock Alert: The Earnings News That Has Ocugen Slipping Today

Nov. 9, 2021 at 3:32 p.m. ET on InvestorPlace.com

Why Carnival Corporation Stock Dropped Today

Nov. 9, 2021 at 1:05 p.m. ET on Motley Fool

3 Dividend Stocks That Should Pay You the Rest of Your Life

Nov. 9, 2021 at 9:28 a.m. ET on Motley Fool

Better COVID Stock: Merck vs. Pfizer

Nov. 9, 2021 at 8:00 a.m. ET on Motley Fool

3 Dow Stocks That Are Screaming Buys in November

Nov. 9, 2021 at 6:06 a.m. ET on Motley Fool

Should You Buy Pfizer Stock After the Fantastic COVID-19 Pill News?

Nov. 9, 2021 at 5:55 a.m. ET on Motley Fool

Analysts Have Conflicting Sentiments on These Healthcare Companies: ChemoCentryx (CCXI), Pfizer (PFE) and Bluebird Bio (BLUE)

Nov. 9, 2021 at 3:35 a.m. ET on TipRanks.com

Why Novavax Stock Jumped Today

Nov. 8, 2021 at 4:32 p.m. ET on Motley Fool

Why BioNTech Stock Is Bouncing Back Today

Nov. 8, 2021 at 12:09 p.m. ET on Motley Fool

Are Vaccine Stocks A Buy On Earnings?

Nov. 8, 2021 at 11:49 a.m. ET on InvestorPlace.com

Why Moderna Stock Faltered In October

Nov. 8, 2021 at 8:56 a.m. ET on Motley Fool

Here's Why Merck Stock Vaulted Higher in October

Nov. 8, 2021 at 8:39 a.m. ET on Motley Fool

Where Will Ocugen Be in 3 Years?

Nov. 8, 2021 at 6:45 a.m. ET on Motley Fool

Do These 2 Numbers From Pfizer Spell Trouble for Moderna?

Nov. 8, 2021 at 6:30 a.m. ET on Motley Fool

Better Buy After Earnings: Moderna or Novavax?

Nov. 8, 2021 at 6:00 a.m. ET on Motley Fool

Pfizer’s PAXLOVID Study Reveals Positive Results; Shares Jump

Nov. 8, 2021 at 1:47 a.m. ET on TipRanks.com

Is Ocugen a Buy?

Nov. 7, 2021 at 6:20 a.m. ET on Motley Fool

Moderna's President Just Gave Us a Clue About the Size of Tomorrow's Vaccine Market

Nov. 7, 2021 at 6:00 a.m. ET on Motley Fool

Will Moderna and Pfizer Continue to Lead After the COVID-19 Pandemic Ends?

Nov. 6, 2021 at 6:04 a.m. ET on Motley Fool

No Headlines Available

Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Name	Chg %	Market Cap
Johnson & Johnson	-0.22%	$428.77B
Eli Lilly & Co.	0.57%	$249.22B
Abbott Laboratories	-0.29%	$224.22B
Merck & Co. Inc.	0.05%	$209.29B
AstraZeneca PLC	-0.45%	£144.55B
AstraZeneca PLC ADR	0.77%	$196.05B
Novartis AG	-0.24%	CHF169.17B
Moderna Inc.	-3.20%	$99.21B
Bristol Myers Squibb Co.	0.08%	$131.87B
Amgen Inc.	0.16%	$119.06B

Competitor Data Provided By